印度尼西亚计划对葛兰素史克、康希诺和 BioNTech 的结核病疫苗进行临床试验，以应对不断上升的病例和死亡人数。 Indonesia plans to conduct clinical trials of TB vaccines from GSK, CanSino, and BioNTech to address rising cases and deaths.

印度尼西亚计划今年开始对葛兰素史克、康希诺生物和 BioNTech 的结核病疫苗进行临床试验，因为该国的结核病病例从 2020 年的 820,000 例增加到 2023 年的预计 100 万例。 Indonesia plans to begin clinical trials of TB vaccines from GlaxoSmithKline, CanSino Biologics, and BioNTech this year, as the country's TB cases rose from 820,000 in 2020 to an estimated 1 million in 2023. 2022年结核病死亡人数达到13.4万人，居世界第二位，引发经济担忧。 TB deaths reached 134,000 in 2022, the second highest in the world, leading to economic concerns. 该国的目标是到2030年将结核病死亡率降低80%，至每10万人中有6人死亡。 The country aims to lower TB mortality rate by 80% to six deaths per 100,000 lives by 2030.